Chicagoest - I don't remember writing anything about a basic and fully diluted MC for public companies so I don't know where your comment came from.

For my own purposes I do my analysis using only the fully diluted number and give myself a low, medium and high range for a future target price. I have found it somewhat challenging over the years with junior companies because there are an additional set of unknowns as a result of their potentially explosive growth if they are able to exacute on their business plans. Speaking of business plans I also tend to build three scenarios for junior companies based on what I believe "could" unfold if different development successes happen as well. With biotech's it becomes even more of a challenge as they tend to only spend money and then, if they are lucky with the science, have a major payday. After all of the above inputs are taken into account plus a few more then I also project prices for fully diluted potential scenarios to come up with potential net amounts to the shareholders in buyout situations. Analysis on manufacturing companies are way easier!

What I like about this company is they have a business person as the CEO so the scientists can focuse on the science. IMO this company would have been finished in 2013 when the ASSURE results came out without this current management structure. It could always be better but business management structure is also part of any analysis. Getting to a Phase III trial is exceptionally challenging for "any" baby biotech. These guys are just a short way away from a FA which could kill us or pave the way to a much rosier picture. 

Someone suggested RVX is now at a launch point, I agree wholeheartedly. From here we either revel in glory or lick our wounds. There are not to many more boxes to get checked off for either scenario to come to fruition.

The analysis, mine or anyone else's suggests it's either time to own this company or walk away. That's just where we seem to be.

All IMO, DYODD

tada